CD26: A novel treatment target for T-cell lymphoid malignancies? (Review)
著者
佐藤, 一也
(Sato, Kazuya)
Dang, NH
上位タイトル
International Journal Of Oncology
Vol.22,
No.3
(2003.
)
,p.481-
497
識別番号
ISSN
1019-6439
抄録
CD26 is a surface glycoprotein with intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity with multiple biological roles, including being intricately involved in immunoregulationas a T-call activation molecule and as a regulator of chemokine function. T-cell lymphoid malignancies represent a hetrogeneous group of diseases that aew generally aggressive and are for the most part resistant to current treatment modalities. Previous studies showed that CD26 is expressed on selected T-cell neoplasms, suggesting a potential role for CD26 in tumor development. We review herein recent classification schemes for T-cell lymphoid malignancies that take into accoung various facets of their clinical presentation. In addition, we discuss findings supporting the conclusion that CD26 has an essential role in human T-cell activation, as well as its ability to regulate the biological effects of selected chemokines through its DPPIV activity. Finally, we will present recent work from our laboratory that indicates a potenrial role for CD26 as a moleculatar target for novel treatment modalities for T-cell lymphoid malignancies.
